CONTACT US for more information
Genetically Engineered Mouse Models (GEMMs)
Replicating Human Cancer Genetics
Genetically Engineered Mouse Models (GEMMs) represent a cutting-edge class of preclinical models, designed to faithfully reproduce the key genetic alterations that drive cancer initiation and progression in humans. Through advanced genetic engineering techniques, specific genes are introduced or modified in the mouse genome, allowing the tumor to develop spontaneously and endogenously in the animal. This precisely mimics the natural process of human carcinogenesis.
Unraveling Tumor-Immune Interactions
Genetically Engineered Mouse Models (GEMMs) represent a cutting-edge class of preclinical models, designed to faithfully reproduce the key genetic alterations that drive cancer initiation and progression in humans. Through advanced genetic engineering techniques, specific genes are introduced or modified in the mouse genome, allowing the tumor to develop spontaneously and endogenously in the animal. This precisely mimics the natural process of human carcinogenesis.
A Living Laboratory of Tumor Pathology
Investigating Carcinogenesis Mechanisms
They allow for the elucidation of how specific mutations contribute to cancer initiation and progression, identifying altered signaling pathways and novel therapeutic targets.
Studying Disease Progression and Relapse
By developing tumors endogenously, GEMMs offer a unique platform to observe disease evolution, the acquisition of treatment resistance, and relapse mechanisms.
Therapeutic Target Validation
They are ideal for validating the biological relevance of new molecular targets and evaluating the efficacy of drugs specifically aimed at these genetic alterations.
Tumor Developmental Biology Research
They enable the study of how the tumor interacts with its physiological microenvironment and how these interactions influence its growth and metastasis.
Available Multiple Myeloma GEMMs
MYC-driven models (MIcy1 & MI)
These models are driven by the overexpression of the MYC oncogene, a key factor in the proliferation and survival of myeloma cells. They are ideal for studying aggressive myelomas and responses to therapies affecting MYC pathways.
BI – Model of SMM Progression
This model is specifically designed to simulate smoldering multiple myeloma (SMM), an asymptomatic stage that precedes active multiple myeloma. It is crucial for investigating the mechanisms driving SMM progression to multiple myeloma and for testing early interventions.
MMSET-BIC – High-risk Myeloma with t(4;14) Translocation
This GEMM reproduces the t(4;14) chromosomal translocation, a high-risk genetic alteration associated with adverse prognosis in myeloma patients. It enables the study of this aggressive subtype and the evaluation of specific therapies.
TP53-BIC – TP53-deleted Aggressive Myeloma
This model features a deletion of the TP53 gene, a tumor suppressor gene whose loss is associated with more aggressive and chemotherapy-resistant myeloma. It is a crucial tool for investigating therapeutic strategies in myelomas with an unfavorable prognosis.
Available Lymphoma GEMMs
MYD88/Cd79b (ABC-DLBCL)
Models reflecting Activated B-cell like Diffuse Large B-cell Lymphoma (ABC-DLBCL), an aggressive subtype. Trp53–/– variant & Blimp1–/– variant
PBIcγ1 (ABC-DLBCL):
Another model of Activated B-cell like Diffuse Large B-cell Lymphoma, focused on the characteristics of activated B cells.
MYD88/Cd79b – LPL – Lymphoplasmacytic Lymphoma
A specific model for Lymphoplasmacytic Lymphoma, an indolent form of lymphoma.
CHIP–MDS–AML
Under Development.
